Therapy of human pancreatic carcinoma based on suppression of HMGA1 protein synthesis in preclinical models (original) (raw)

• Warshaw AL, Fernandez-del Castillo C . Pancreatic carcinoma. N Engl J Med. 1992;326:455–465.
  Article CAS PubMed Google Scholar
• Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg. 1995;221:721–731 discussion 731–733.
  CAS PubMed PubMed Central Google Scholar
• Landis SH, Murray T, Bolden S, Wingo PA . Cancer statistics, 1999. CA Cancer J Clin. 1999;49:8–31.
  CAS PubMed Google Scholar
• Johnson KR, Lehn DA, Elton TS, Barr PJ, Reeves R . Complete murine cDNA sequence, genomic structure, and tissue expression of the high mobility group protein HMG-I(Y). J Biol Chem. 1988;263:18338–18342.
  CAS PubMed Google Scholar
• Johnson KR, Lehn DA, Reeves R . Alternative processing of mRNAs encoding mammalian chromosomal high-mobility-group proteins HMG-I and HMG-Y. Mol Cell Biol. 1989;9:2114–2123.
  Article CAS PubMed PubMed Central Google Scholar
• Manfioletti G, Giancotti V, Bandiera A, et al. cDNA cloning of the HMGI-C phosphoprotein, a nuclear protein associated with neoplastic and undifferentiated phenotypes. Nucleic Acids Res. 1991;19:6793–6797.
  Article CAS PubMed PubMed Central Google Scholar
• Grosschedl R, Giese K, Pagel J . HMG domain proteins: architectural elements in the assembly of nucleoprotein structures. Trends Genet. 1994;10:94–100.
  Article CAS PubMed Google Scholar
• Lovell-Badge R . Developmental genetics. Living with bad architecture. Nature. 1995;376:725–726.
  Article CAS PubMed Google Scholar
• Bustin M, Reeves R . High-mobility-group chromosomal proteins: architectural components that facilitate chromatin function. Prog Nucleic Acid Res Mol Biol. 1996;54:35–100.
  Article CAS PubMed Google Scholar
• Zhou X, Benson KF, Ashar HR, Chada K . Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C. Nature. 1995;376:771–774.
  Article CAS PubMed Google Scholar
• Chiappetta G, Avantaggiato V, Visconti R, et al. High level expression of the HMGI (Y) gene during embryonic development. Oncogene. 1996;13:2439–2446.
  CAS PubMed Google Scholar
• Chiappetta G, Bandiera A, Berlingieri MT, et al. The expression of the high mobility group HMGI (Y) proteins correlates with the malignant phenotype of human thyroid neoplasias. Oncogene. 1995;10:1307–1314.
  CAS PubMed Google Scholar
• Tamimi Y, van der Poel HG, Karthaus HF, Debruyne FM, Schalken JA . A retrospective study of high mobility group protein I(Y) as progression marker for prostate cancer determined by in situ hybridization. Br J Cancer. 1996;74:573–578.
  Article CAS PubMed PubMed Central Google Scholar
• Fedele M, Bandiera A, Chiappetta G, et al. Human colorectal carcinomas express high levels of high mobility group HMGI(Y) proteins. Cancer Res. 1996;56:1896–1901.
  CAS PubMed Google Scholar
• Chiappetta G, Tallini G, De Biasio MC, et al. Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma. Cancer Res. 1998;58:4193–4198.
  CAS PubMed Google Scholar
• Bandiera A, Bonifacio D, Manfioletti G, et al. Expression of HMGI(Y) proteins in squamous intraepithelial and invasive lesions of the uterine cervix. Cancer Res. 1998;58:426–431.
  CAS PubMed Google Scholar
• Abe N, Watanabe T, Sugiyama M, et al. Determination of high mobility group I(Y) expression level in colorectal neoplasias: a potential diagnostic marker. Cancer Res. 1999;59:1169–1174.
  CAS PubMed Google Scholar
• Abe N, Watanabe T, Masaki T, et al. Pancreatic duct cell carcinomas express high levels of high mobility group I(Y) proteins. Cancer Res. 2000;60:3117–3122.
  CAS PubMed Google Scholar
• Chiappetta G, Manfioletti G, Pentimalli F, et al. High mobility group HMGI(Y) protein expression in human colorectal hyperplastic and neoplastic diseases. Int J Cancer. 2001;91:147–151.
  Article CAS PubMed Google Scholar
• Berlingieri MT, Manfioletti G, Santoro M, et al. Inhibition of HMGI-C protein synthesis suppresses retrovirally induced neoplastic transformation of rat thyroid cells. Mol Cell Biol. 1995;15:1545–1553.
  Article CAS PubMed PubMed Central Google Scholar
• Berlingieri MT, Pierantoni GM, Giancotti V, Santoro M, Fusco A . Thyroid cell transformation requires the expression of the HMGA1 proteins. Oncogene. 2002;21:2971–2980.
  Article CAS PubMed Google Scholar
• Wood LJ, Maher JF, Bunton TE, Resar LM . The oncogenic properties of the HMG-I gene family. Cancer Res. 2000;60:4256–4261.
  CAS PubMed Google Scholar
• Baldassarre G, Fedele M, Battista S, et al. Onset of natural killer cell lymphomas in transgenic mice carrying a truncated HMGI-C gene by the chronic stimulation of the IL-2 and IL-15 pathway. Proc Natl Acad Sci USA. 2001;98:7970–7975.
  Article CAS PubMed PubMed Central Google Scholar
• Fedele M, Battista S, Kenyon L, et al. Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene. 2002;21:3190–3198.
  Article CAS PubMed Google Scholar
• Scala S, Portella G, Fedele M, Chiappetta G, Fusco A . Adenovirus-mediated suppression of HMGI(Y) protein synthesis as potential therapy of human malignant neoplasias. Proc Natl Acad Sci USA. 2000;97:4256–4261.
  Article CAS PubMed PubMed Central Google Scholar
• Milner AE, Levens JM, Gregory CD . Flow cytometric methods of analyzing apoptotic cells. Methods Mol Biol. 1998;80:347–354.
  Article CAS PubMed Google Scholar
• Pellegata NS, Sessa F, Renault B, et al. K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res. 1994;54:1556–1560.
  CAS PubMed Google Scholar
• Redston MS, Caldas C, Seymour AB, et al. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res. 1994;54:3025–3033.
  CAS PubMed Google Scholar
• Rosenberg L . Pancreatic cancer: a review of emerging therapies. Drugs. 2000;59:1071–1089.
  Article CAS PubMed Google Scholar
• Schwarte-Waldhoff I, Volpert OV, Bouck NP, et al. Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. Proc Natl Acad Sci USA. 2000;97:9624–9629.
  Article CAS PubMed PubMed Central Google Scholar
• Jaffee EM, Hruban RH, Canto M, Kern SE . Focus on pancreas cancer. Cancer Cell. 2002;2:25–28.
  Article CAS PubMed Google Scholar
• Hao D, Rowinsky EK . Inhibiting signal transduction: recent advances in the development of receptor tyrosine kinase and Ras inhibitors. Cancer Invest. 2002;20:387–404.
  Article CAS PubMed Google Scholar
• Bouvet M, Bold RJ, Lee J, et al. Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer. Ann Surg Oncol. 1998;5:681–688.
  Article CAS PubMed Google Scholar
• Ghaneh P, Greenhalf W, Humphreys M, et al. Adenovirus-mediated transfer of p53 and p16(INK4a) results in pancreatic cancer regression in vitro and in vivo. Gene Therapy. 2001;8:199–208.
  Article CAS PubMed Google Scholar
• Joshi US, Dergham ST, Chen YQ, et al. Inhibition of pancreatic tumor cell growth in culture by p21WAF1 recombinant adenovirus. Pancreas. 1998;16:107–113.
  Article CAS PubMed Google Scholar
• Dumon KR, Ishii H, Vecchione A, et al. Fragile histidine triad expression delays tumor development and induces apoptosis in human pancreatic cancer. Cancer Res. 2001;15:4827–4836.
  Google Scholar
• Takeuchi M, Shichinohe T, Senmaru N, et al. The dominant negative H-ras mutant, N116Y, suppresses growth of metastatic human pancreatic cancer cells in the liver of nude mice. Gene Therapy. 2000;7:518–526.
  Article CAS PubMed Google Scholar
• Bardeesy N, DePinho RA . Pancreatic cancer biology and genetics. Nat Rev Cancer. 2002;2:897–909.
  Article CAS PubMed Google Scholar
• Laheru D, Biedrzycki B, Jaffee EM . Immunologic approaches to the management of pancreatic cancer. Cancer J. 2001;7:324–337.
  CAS PubMed Google Scholar
• Mulvihill S, Warren R, Venook A, et al. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Therapy. 2001;8:308–315.
  Article CAS PubMed Google Scholar
• Rodicker F, Stiewe T, Zimmermann S, Putzer BM . Therapeutic efficacy of E2F1 in pancreatic cancer correlates with TP73 induction. Cancer Res. 2001;61:7052–7055.
  CAS PubMed Google Scholar
• Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD . How cells respond to interferons. Annu Rev Biochem. 1998;67:227–264.
  Article CAS PubMed Google Scholar
• Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in mammalian cell culture. Nature. 2001;411:494–498.
  Article CAS PubMed Google Scholar
• Caplen NJ, Parrish S, Imani F, Fire A, Morgan RA . Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc Natl Acad Sci USA. 2001;98:9742–9747.
  Article CAS PubMed PubMed Central Google Scholar
• Bitko V, Barik S . Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses. BMC Microbiol. 2001;1:34.
  Article CAS PubMed PubMed Central Google Scholar